| Avastin |
All Financial Data in US $ (mln) |
| Word Search (Top 10 - by date) |
PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech PDL BioPharma
(September 01, 2010)
|
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment Idera Pharmaceuticals
(August 27, 2010)
|
Promising Data in Liver Metastases Clinical Trial Biocompatibles International
(August 26, 2010)
|
Announcement Of Interim Report Q2 2010 Affitech
(August 26, 2010)
|
Liver Metastases Clinical Trial referenced by Cancer Research UK Biocompatibles International
(August 13, 2010)
|
PDL BioPharma Receives Letter from Genentech Relating to European Patents PDL BioPharma
(August 13, 2010)
|
Affitech Announces New Scientific Findings Affitech
(August 09, 2010)
|
Synta Pharmaceuticals Reports Second-Quarter 2010 Financial Results and Clinical Update Synta Pharmaceuticals
(August 09, 2010)
|
Avastin Shows Longest Overall Survival for Patients With Adenocarcinoma, The Most Common Type of Advanced Lung Cancer Roche
(August 06, 2010)
|
Lpath, the Category Leader of Lipidomics-Based Therapeutics, Provides Status Update and Outlines Near-Term Goals Lpath
(August 05, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
| Summary Product Name Information |
|
|
| Product Sales Summary 2007/08 |
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2007 |
2008
|
2008 |
| Avastin2 |
|
|
|
5,722 |
7,504 |
|
+31% |
|
|
Note: Shaded Cells3 |
|
|
More Product Information for EvaluatePharma® subscribersSubscribers see:
- Sales (historic and forecast to 2016 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
- Details of all events impacting the product
- Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)
|
Register to access more FREE content:
- 2009 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
|
|
|
|